Tirzepatide vs Semaglutide: How the Two Medicines Differ, in Plain Language

Somewhere in the past year, the question stopped being whether these medicines work and became which one. You can hear it in waiting rooms and read it in comment threads: a sister-in-law who switched, a coworker whose nausea settled after a swap, a headline claiming one drug beats the other by nearly half. The search phrase tirzepatide vs semaglutide has become shorthand for a very personal calculation.

The spark was real science, not just chatter. In May 2025, the first large trial to pit the two directly against each other, SURMOUNT-5, appeared in the New England Journal of Medicine. Since then the pace has not slowed: new approved uses for each drug, a daily pill version of semaglutide, and a steady stream of viral claims about muscle, mood and “the stronger one.”

As of January 2026, here is what the evidence supports, where it is thin, and why the honest answer to which is better still begins with the word depends.

What changed recently in the tirzepatide vs semaglutide story

For years, comparing these two drugs meant lining up separate trials that used different people, different lengths and different rules. That indirect method always came with an asterisk. The asterisk shrank in May 2025, when SURMOUNT-5 was published. It randomly assigned 751 adults living with obesity but not diabetes to either tirzepatide or semaglutide for 72 weeks, with both drugs pushed to their highest tolerated approved strengths. Tirzepatide came out ahead on every weight measure the trial set out to test.

Regulators have also been busy widening the labels. In December 2024, US regulators approved tirzepatide for moderate-to-severe obstructive sleep apnea in adults with obesity, the first medicine cleared for that purpose. In August 2025, semaglutide gained approval for metabolic dysfunction-associated steatohepatitis, a form of liver inflammation driven by fat build-up, after the ESSENCE trial showed improved liver biopsies. Late 2025 brought a once-daily oral form of semaglutide for weight management, ending the assumption that these medicines must be injected.

Cardiovascular evidence moved too. Semaglutide’s SELECT trial, published in late 2023, had already shown a 20% relative reduction in heart attacks, strokes and cardiovascular deaths among people with existing heart disease and excess weight. In 2025, the SURPASS-CVOT trial reported that tirzepatide was at least as protective as dulaglutide, an older GLP-1 medicine, in people with type 2 diabetes and heart disease. That is reassuring, but it is a comparison against another active drug, not against placebo, and it was in diabetes rather than obesity alone.

One more shift belongs here. Both medicines are now cleared in the US for chronic weight management and for type 2 diabetes under different brand names, and both are on national formularies in several countries. The NHS, for example, describes weight-management medicines as one part of a specialist program that includes diet and activity support. Availability has widened, which is partly why so many people are now asking the comparison question at all.

What is semaglutide and how does it work?

Semaglutide is a synthetic copy of GLP-1, a hormone your small intestine releases within minutes of eating. GLP-1 stands for glucagon-like peptide-1; in plain terms it is a messenger that tells your body food has arrived. The natural hormone lasts only a few minutes before an enzyme breaks it down. Semaglutide has been chemically altered so it lasts about a week, which is why it is taken weekly rather than with every meal.

Once in the bloodstream it does four things at once. It prompts the pancreas to release insulin only when blood sugar is high, so on its own it rarely causes dangerous lows. It suppresses glucagon, the hormone that tells the liver to dump stored sugar. It slows the rate at which the stomach empties, so meals feel filling for longer. And it acts on appetite centers in the brainstem and hypothalamus, quieting the pull toward food that many people describe as constant background noise.

The weight-loss effect is mostly the brain effect. In the STEP 1 trial, 1,961 adults with obesity took semaglutide or placebo for 68 weeks alongside lifestyle advice. The semaglutide group lost an average of just under 15% of starting body weight; the placebo group lost about 2.4%. Roughly one in three semaglutide participants lost a fifth of their body weight or more, a result previously associated only with surgery.

Semaglutide is sold under three names, and the distinction matters for this comparison. Ozempic is the injectable version approved for type 2 diabetes. Wegovy is the version approved for chronic weight management, for reducing cardiovascular risk in people with heart disease and excess weight, and now for MASH. Rybelsus is a daily tablet for diabetes. The molecule is identical; what differs is the approved purpose and the strengths studied. MedlinePlus lists each separately for exactly that reason.

What is tirzepatide and why is it called a dual agonist?

Tirzepatide is a single molecule built to fit two different locks. Like semaglutide it activates the GLP-1 receptor. It also activates the receptor for GIP, glucose-dependent insulinotropic polypeptide, a second gut hormone released mainly from the upper small intestine. An agonist is simply a substance that switches a receptor on, so a dual agonist switches on two.

Why add GIP? For decades it was considered the less useful hormone, because in people with type 2 diabetes it seemed to lose its effect on insulin. Animal and early human work suggested the pairing might do something neither hormone does alone. GIP receptors are found in fat tissue, where they may improve how fat cells store and release energy, and in appetite regions of the brain. Some researchers think GIP activation also blunts the nausea that GLP-1 alone can trigger, which would help explain why tirzepatide can be pushed to strong effects with side-effect rates similar to semaglutide. That mechanism remains a working hypothesis, not a settled fact.

Whatever the explanation, the numbers were striking. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus a weight-related condition, excluding diabetes, and followed them for 72 weeks. Average weight loss at the highest studied strength was about 21%, against roughly 3% on placebo. More than half of participants at that strength lost at least a fifth of their body weight, and a third lost a quarter or more.

Tirzepatide is also sold under two names. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. The pharmacology is the same; the labels differ. Tirzepatide’s half-life is roughly five days, a touch shorter than semaglutide’s, which has practical implications if a dose is missed. Those details belong to the prescriber’s conversation, not to a magazine.

Mounjaro vs Ozempic: the same debate wearing diabetes labels

Ask about Mounjaro vs Ozempic and you are really asking tirzepatide vs semaglutide in people with type 2 diabetes. Here the head-to-head data arrived years before the obesity trial, and it tells a consistent story.

SURPASS-2, published in 2021, randomly assigned 1,879 adults with type 2 diabetes already taking metformin to one of three strengths of tirzepatide or to the semaglutide strength then approved for diabetes. After 40 weeks, every tirzepatide group had a larger drop in HbA1c, the three-month average blood-sugar marker, than the semaglutide group. The difference ranged from about 0.15 to 0.45 percentage points depending on strength, which sounds small but is clinically meaningful when both drugs are already lowering HbA1c by around two points. Weight loss was also greater with tirzepatide, by roughly four to twelve additional pounds.

A fair-minded reader should note a limitation that critics raised immediately. The semaglutide comparator was the diabetes strength, not the higher strength later approved for weight management. Some of tirzepatide’s advantage in SURPASS-2 may reflect that mismatch. SURMOUNT-5 addressed this in the obesity setting by allowing semaglutide to reach its top approved strength, and the gap, while narrower, persisted.

Where do the two diabetes labels stand on heart protection? Ozempic carries an approved indication for reducing major cardiovascular events in adults with type 2 diabetes and established heart disease, based on the SUSTAIN-6 trial. It has also been approved to slow kidney decline in diabetes after the FLOW trial showed a 24% relative reduction in serious kidney outcomes. Mounjaro does not yet carry a comparable label. The 2025 SURPASS-CVOT trial showed tirzepatide was non-inferior to dulaglutide, itself a heart-protective GLP-1 drug, which is encouraging evidence but a different kind of proof from a placebo-controlled win.

For a person with diabetes, then, the choice is not simply which lowers sugar more. It weighs stronger glucose and weight effects against a longer and more specific track record of organ protection.

Zepbound vs Mounjaro: one molecule, two purposes

Zepbound vs Mounjaro confuses more people than any other pairing in this space, and the answer is disarmingly simple: they contain the same active drug, tirzepatide, manufactured by the same company. What separates them is the approved use printed on the label.

Mounjaro is approved to improve blood sugar in adults with type 2 diabetes, alongside diet and exercise. Zepbound is approved for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition such as high blood pressure or high cholesterol, and separately for moderate-to-severe obstructive sleep apnea in adults with obesity. When regulators approved the sleep apnea use in December 2024, they cited the SURMOUNT-OSA trials, in which participants experienced roughly 25 to 29 fewer breathing interruptions per hour of sleep than those on placebo, with about half reaching a level where the condition was considered resolved or mild.

Why maintain two names at all? Partly regulatory history: the diabetes approval came first, in 2022, and the weight approval in late 2023 after separate trials in people without diabetes. Partly practical: keeping the indications distinct helps prescribers, pharmacists and insurers match a medicine to the condition it has been proven to treat. The same logic explains Ozempic and Wegovy.

The distinction matters for a comparison article in one specific way. When people say tirzepatide beat semaglutide, they are usually citing SURMOUNT-5, which used the weight-management products, Zepbound and Wegovy. When they cite SURPASS-2, they mean the diabetes products, Mounjaro and Ozempic. Both trials favor tirzepatide, but they answer different questions in different populations. Mixing them up leads to the kind of confident, wrong statements that circulate online.

One caution belongs here because it is frequently asked: using a diabetes-labeled product for weight loss in someone without diabetes is off-label. The evidence base for the molecule is strong, but whether that is appropriate for a particular person is a decision for the treating clinician, who is accountable for it.

Tirzepatide vs semaglutide for weight loss: what the head-to-head trial found

SURMOUNT-5 is the trial everyone is quoting, so it deserves a careful look. Participants were adults with a body mass index of 30 or higher, or 27 or higher with a weight-related condition, and none had diabetes. Both groups received the same lifestyle counseling. Doses were increased stepwise in the manner the labels describe, and each group could reach its highest approved strength. The primary question was percentage change in body weight at 72 weeks.

The table below summarizes the key outcomes as reported in the published paper.

Outcome at 72 weeks	Tirzepatide	Semaglutide
Average weight change	about -20.2%	about -13.7%
Lost 15% or more of body weight	about 65%	about 40%
Lost 25% or more of body weight	about 32%	about 16%
Waist circumference change	about -18 cm	about -13 cm
Stopped because of side effects	about 6%	about 8%
Gastrointestinal side effects	mostly mild to moderate, similar rates	mostly mild to moderate, similar rates

The relative difference works out to roughly 47% more weight lost on tirzepatide, which is the number that launched a thousand headlines. Notice what the table also shows: semaglutide produced weight loss that would have been considered remarkable a decade ago, and one in six people on it lost a quarter of their body weight. This was not a failure of one drug; it was a comparison of two effective ones.

Limitations the authors themselves flagged: the trial was open-label, meaning participants knew which drug they received, which can nudge behavior. It was funded by tirzepatide’s manufacturer, though run with independent statistical oversight. And 72 weeks tells us about a year and a half, not about the decades most people would take these medicines. Individual responses varied widely in both groups; averages describe crowds, not you.

What the evidence actually says, graded by strength

Not every claim in this debate rests on the same footing. It helps to sort them.

Strong evidence, from randomized controlled trials. Both medicines produce clinically meaningful weight loss in adults with obesity compared with placebo; SURMOUNT-1 and STEP 1 each enrolled about 2,000 to 2,500 people. Tirzepatide produces greater average weight loss than semaglutide in adults without diabetes, based on one large open-label head-to-head trial, SURMOUNT-5. Tirzepatide lowers HbA1c more than the diabetes strength of semaglutide, from SURPASS-2. Semaglutide reduces major cardiovascular events in people with heart disease and excess weight without diabetes, from SELECT, which followed more than 17,000 people for over three years. Semaglutide slows kidney decline in type 2 diabetes with chronic kidney disease, from FLOW. Tirzepatide improves obstructive sleep apnea in obesity, from SURMOUNT-OSA.

Moderate evidence, or strong evidence answering a slightly different question. Tirzepatide protects the heart in type 2 diabetes at least as well as dulaglutide, from SURPASS-CVOT. Because dulaglutide itself beat placebo in an earlier trial, this is meaningful, but it is not the same as a direct placebo-controlled demonstration in people with obesity alone. A dedicated tirzepatide cardiovascular trial in obesity is still under way.

Observational data, useful but prone to bias. Real-world comparisons of the two drugs in insurance databases have generally echoed the trial ranking, with larger weight loss on tirzepatide. These studies cannot fully account for who was chosen for which drug, or for who kept taking it.

Expert opinion or mechanism, not outcome data. The idea that GIP activation reduces nausea, protects muscle, or improves fat metabolism in humans rests on biological plausibility and small studies. It may be true. It has not been proven in the way weight loss has.

A reader who keeps these tiers in mind will notice that the most viral claims tend to live in the bottom two, while the most consequential, heart protection, lives at the top and currently favors semaglutide’s evidence base.

Heart, kidneys, liver and sleep: where the proven benefits diverge

Weight is the headline, but the reason clinicians care about weight is what it does to organs. On that front the two medicines have followed different research paths, and the labels reflect it.

Semaglutide has the deeper cardiovascular file. SELECT enrolled 17,604 adults aged 45 and over with established heart disease and a BMI of 27 or higher, none with diabetes. Over a median of about 40 months, 6.5% of the semaglutide group had a heart attack, stroke or cardiovascular death, compared with 8.0% on placebo. That is a 20% relative risk reduction, and it appeared early, before most of the weight had come off, which suggests effects beyond weight alone. The result earned semaglutide an approved indication for cardiovascular risk reduction in March 2024. The FLOW trial added a 24% relative reduction in serious kidney events in people with type 2 diabetes and kidney disease. In 2025, the ESSENCE trial showed resolution of liver inflammation without worsening scarring in significantly more people with MASH on semaglutide than on placebo.

Tirzepatide’s file is newer and pointed in different directions. SURMOUNT-OSA delivered a first-in-class approval for sleep apnea in obesity. In SUMMIT, tirzepatide reduced heart-failure worsening and deaths in people with obesity and a type of heart failure where the heart pumps normally but fills stiffly, by about 38% relative to placebo. SURPASS-CVOT confirmed it does not lag dulaglutide on major cardiovascular events in diabetes. A large placebo-controlled cardiovascular outcomes trial in obesity without diabetes, SURMOUNT-MMO, is expected to report in the coming years.

What does this mean for a person choosing between them? If the priority is preventing a second heart attack in someone who has already had one, semaglutide has direct evidence for that exact situation. If the priority is sleep apnea or a specific form of heart failure alongside weight, tirzepatide has direct evidence. For blood sugar in diabetes, tirzepatide lowers it more; for kidney protection in diabetes, semaglutide has the specific trial. These are not marketing distinctions. They are the difference between a benefit shown in a randomized trial and one reasonably hoped for.

What makes you less sick, semaglutide or tirzepatide?

Nausea is the side effect that makes or breaks these medicines for many people, so the question deserves a straight answer: in the only direct comparison, the two drugs caused gastrointestinal side effects at similar rates.

Both work partly by slowing stomach emptying, and both act on brainstem regions involved in nausea. The common effects are the same list for each: nausea, diarrhea, constipation, vomiting, indigestion, belching and reduced appetite that can tip into food aversion. In SURMOUNT-5, most events were mild to moderate and clustered during the months when the dose was being stepped up. Slightly fewer people on tirzepatide stopped because of side effects, about 6% versus about 8%, but the difference was small and the trial was not designed to prove one drug is gentler.

Looking across the separate placebo-controlled trials adds texture without changing the conclusion. In STEP 1, about 44% of semaglutide participants reported nausea at some point over 68 weeks, against 17% on placebo. In SURMOUNT-1, nausea affected roughly a quarter to a third of tirzepatide participants depending on strength, against about 10% on placebo. Those numbers look like a win for tirzepatide until you remember that different trials, different questionnaires and different populations make cross-trial percentages unreliable. The head-to-head data is the better guide, and it says: about the same.

Individual experience varies more than the averages suggest. Some people feel queasy on one and fine on the other for reasons nobody can predict. The practical levers are the same for both: slower stepping up of the dose under the prescriber’s direction, smaller meals, less fat and alcohol, and time. Mayo Clinic and Cleveland Clinic both note that gastrointestinal effects usually ease as the body adjusts.

Less common but more serious effects also overlap. Both labels warn about pancreatitis, gallbladder disease, dehydration leading to kidney injury, low blood sugar when combined with insulin or sulfonylureas, and a boxed warning about thyroid C-cell tumors seen in rodents, which has not been demonstrated in humans but leads to avoidance in people with certain thyroid cancer histories. Neither drug has a safety edge here that the evidence can support.

Do you lose more muscle on semaglutide or tirzepatide?

Any rapid weight loss, whether from a medicine, surgery or a strict diet, removes some lean mass along with fat. Lean mass is everything that is not fat: muscle, but also bone, organs and water. The worry is that a drug that shrinks appetite dramatically could strip muscle in a way that leaves people weaker or frailer, particularly older adults.

Here is what the trials measured. A subgroup of STEP 1 participants had body composition scans; about 40% of the weight semaglutide participants lost was lean mass and about 60% was fat, and the proportion of their body that was fat fell meaningfully. A similar substudy in SURMOUNT-1 found that roughly 25% of the weight lost on tirzepatide was lean mass and about 75% was fat. Read quickly, that looks like tirzepatide spares muscle better.

Read carefully, it does not settle the question. The two substudies used different participants, different scanning schedules and different total weight loss; when more total weight comes off, the fat proportion often rises. The ratios fall within the range seen in non-drug weight loss, where lean mass typically accounts for a quarter to a third of the loss. SURMOUNT-5, the direct comparison, did not include body composition as a main outcome. There is currently no randomized head-to-head evidence that either drug preserves muscle better than the other. Claims that GIP activation protects muscle rest on mechanism and small studies, which places them in the expert-opinion tier.

Two things matter more than which drug you take. Resistance training two or more days a week and adequate protein have repeatedly been shown to preserve lean mass during weight loss, in trials that had nothing to do with these medicines. The NIH’s weight-management guidance lists both as part of any medically supervised program. Trials are now under way combining these drugs with muscle-preserving compounds, an acknowledgment that the question is real and still open. If strength or frailty is a concern, it is a specific point to raise with the prescriber rather than a reason to pick one molecule over the other on current data.

How long does it take to lose 20 lbs on tirzepatide, or on semaglutide?

The honest answer starts with a reframing. Twenty pounds means something different for a person starting at 180 pounds, where it is 11% of body weight, than for someone at 300 pounds, where it is under 7%. Trials report percentages for this reason, and translating them back into pounds requires your own starting number.

With that caveat, the trial curves give a rough shape. In SURMOUNT-1, the average participant, who started at around 231 pounds, had lost about 7% of body weight by week 12 and roughly 15% by around week 36 at the higher strengths; that is about 16 pounds at three months and 35 pounds at eight or nine months on average. In STEP 1, where the average starting weight was about 232 pounds, semaglutide participants had lost around 6% at week 12 and approximately 10% by week 20, which corresponds to about 14 pounds and 23 pounds respectively. In both trials weight continued falling, more slowly, until it leveled off somewhere between a year and 18 months.

So a person of average trial weight might cross the 20-pound mark around three to four months on tirzepatide and around four to five months on semaglutide, if their response matched the average. Many people do not. In every trial a meaningful minority lost far less than the mean, and some lost far more. Early loss during the first months, when the dose is still being stepped up, tends to predict later response, which is why prescribers often reassess at that point.

Two points keep this from becoming a race. First, the slow stepping-up period exists to reduce nausea, and rushing it does not help; the labels describe the schedule and only the prescriber should adjust it. Second, the plateau is not failure. It is the body reaching a new balance between appetite, intake and energy use. Whether that plateau lands in a healthier place matters more than the calendar date on which 20 pounds disappeared.

Why would a doctor prescribe semaglutide instead of tirzepatide?

If tirzepatide wins on average weight loss, the choice of semaglutide can look puzzling from the outside. In practice clinicians reach for it regularly, for reasons that have little to do with the headline number.

The strongest is cardiovascular evidence. A patient who has already had a heart attack or stroke sits squarely in the population SELECT studied, and semaglutide carries an approved indication to reduce the risk of another event in exactly that group. For a clinician whose first duty is preventing death and disability, a proven 20% relative reduction can outweigh an extra several percentage points of weight loss. The same logic applies to someone with type 2 diabetes and chronic kidney disease, where FLOW gives semaglutide specific kidney evidence, and to someone with confirmed MASH.

Formulation is a second reason. Semaglutide exists as a daily tablet for diabetes and, since late 2025, as a daily tablet for weight management. For a person who cannot or will not use injections, that removes the comparison entirely.

Track record is a third. Semaglutide has been prescribed to more people for more years, including through the SELECT trial’s three-plus years of follow-up. Some prescribers prefer the longer safety window, particularly for patients they expect to treat for decades. Others have seen an individual patient tolerate semaglutide better, or have a patient who is already stable on it and has no reason to change.

Access and coverage shape choices too, though the details vary by country and insurer and belong in the clinic rather than in an article. So do drug interactions, pregnancy plans, a history of pancreatitis or gallbladder disease, and the specific modest weight goal that may not need the stronger agent.

None of this means tirzepatide is the wrong choice for someone whose primary goal is weight loss or blood-sugar control and who has no heart history. It means a clinician who picks semaglutide is usually weighing an organ-protection file against a weight-loss file, and that trade is legitimate. If you do not understand why one was chosen for you, asking is reasonable; switching without that conversation is not.

Common myths about tirzepatide and semaglutide, corrected

Viral claims travel faster than trial results. A few of the most common deserve correction.

Myth: tirzepatide is just a stronger dose of the same thing. They are different molecules with different targets. Tirzepatide activates both the GLP-1 and GIP receptors; semaglutide activates GLP-1 alone. Whether the second receptor explains the extra weight loss is still being worked out, but the drugs are not interchangeable strengths of one product.

Myth: semaglutide is obsolete. Semaglutide holds approved indications, backed by randomized trials, for cardiovascular risk reduction, kidney protection in diabetes and MASH that tirzepatide does not yet have. For some patients it remains the evidence-based first choice.

Myth: one of them melts muscle and the other protects it. Both remove some lean mass along with fat, in proportions similar to other forms of weight loss. There is no head-to-head body-composition trial. Strength training and protein have far better evidence for muscle preservation than the choice of molecule.

Myth: you can stop once the weight is off. In SURMOUNT-4, people switched from tirzepatide to placebo after 36 weeks regained about 14% of body weight over the following year while those who continued lost a further 5.5%. Semaglutide’s STEP 1 extension showed regain of about two-thirds of lost weight within a year of stopping. Both are treatments for a chronic condition, and any change belongs to the prescriber.

Myth: compounded or online versions are the same medicine. Compounded products are made by pharmacies rather than the original manufacturer and are not approved or reviewed for safety, effectiveness or quality by the FDA. Products sold as research peptides are not approved medicines and are not intended for human use. Regulators in several countries have issued warnings about dosing errors and counterfeit products. They are not a substitute for a prescription and not for self-use.

Myth: the drugs cause suicidal thoughts. Reviews by US and European regulators, completed in 2024, found no evidence of a causal link, though monitoring continues and mood changes should always be reported.

Myth: side effects mean the drug is not right for you. Most gastrointestinal effects appear during dose escalation and fade. Persistent or severe symptoms are a reason to call the prescriber, not to conclude the medicine has failed.

What happens when you stop, and what long-term use looks like

The most under-discussed part of the tirzepatide vs semaglutide comparison is what happens after the trial ends. Obesity is now treated as a chronic, relapsing condition, and the data on stopping these medicines is what changed that framing.

Semaglutide’s STEP 1 extension followed participants for a year after treatment ended. On average they regained about two-thirds of the weight they had lost, and most of the improvements in blood pressure, cholesterol and blood sugar drifted back toward baseline. Tirzepatide’s SURMOUNT-4 was built specifically to test withdrawal: after 36 weeks of treatment, participants were randomly assigned to continue or switch to placebo for another year. Those who continued lost a further 5.5%. Those on placebo regained about 14%, though they remained below their original weight. The pattern is the same for both drugs and mirrors what happens when any effective treatment for a chronic condition is withdrawn: blood pressure rises when antihypertensives stop, too.

This has three practical implications. First, neither drug is a course you complete. Second, the comparison question is really about which medicine a person can take, tolerate and benefit from for years, not which produces the fastest first six months. Third, decisions to pause, reduce or stop, including for planned pregnancy, surgery or side effects, need to be made with the prescriber, who can plan for what follows. Both labels advise discussing pregnancy plans in advance, and both recommend telling an anesthesia team about the medicine before any procedure because slowed stomach emptying raises the risk of inhaling stomach contents.

Long-term safety data is accumulating rather than complete. Semaglutide has the longest follow-up, with SELECT’s more than three years in over 17,000 people showing no new safety signals. Tirzepatide’s longest trials run around two to three years. Neither has the decades of experience that older diabetes drugs have. That is not a reason for alarm; it is a reason for the regular follow-up that both labels require and for candid conversations about how long a person expects to stay on treatment. Researchers are also studying whether lower maintenance strengths, less frequent dosing or planned tapering can hold weight after the initial loss. Until those trials report, the evidence supports continued treatment under supervision.

Who might not be a candidate for either medicine?

The eligibility criteria on the two labels are nearly identical, which is one more reason the comparison is between two similar tools rather than two categories of drug.

For weight management, both are approved for adults with a body mass index of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, abnormal cholesterol or sleep apnea. Semaglutide is also approved for adolescents aged 12 and older with obesity; tirzepatide’s weight indication is currently adult-only in the US, with pediatric trials ongoing. BMI is an imperfect screen, and clinicians increasingly weigh waist size, metabolic markers and the presence of complications alongside it.

Both labels list the same major reasons for caution or avoidance. A personal or family history of medullary thyroid cancer or of multiple endocrine neoplasia type 2, a rare inherited syndrome, is a contraindication for both because of the rodent thyroid findings. A prior serious allergic reaction to the drug or its ingredients rules it out. Pregnancy is a reason not to use either, and both labels advise planning ahead with the prescriber if pregnancy is intended. Breastfeeding data is limited.

Relative cautions include a history of pancreatitis, active gallbladder disease, severe gastrointestinal disease such as gastroparesis, and diabetic eye disease, since rapid improvement in blood sugar can temporarily worsen retinopathy. People taking insulin or sulfonylureas need their other diabetes medicines reviewed to avoid low blood sugar. Anyone with a history of an eating disorder needs careful assessment, because appetite suppression can interact badly with restrictive patterns. Older adults, people with kidney impairment and those on medicines with a narrow margin, such as warfarin or some oral contraceptives with tirzepatide, need specific attention.

None of these lists is a self-assessment tool. They exist to prompt a conversation. The prescriber’s job is to weigh them against the potential benefit for a specific person, which is why neither medicine is available without that assessment and why the NHS and NIH both describe them as one component of a supervised program rather than a standalone product.

When to see a doctor

Both medicines require prescription and regular follow-up, and both labels are explicit about symptoms that should not wait. Whichever drug you take, or if you are deciding between them, these are the moments to seek care.

Seek urgent or emergency care for:

• Severe, persistent abdominal pain, especially pain that spreads to the back, with or without vomiting. This can signal pancreatitis, an inflammation of the pancreas that both labels warn about.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or clay-colored stools, which can indicate gallbladder problems.
• Vomiting or diarrhea that prevents you from keeping fluids down for more than a day, or signs of dehydration such as dizziness, very dark urine or passing little urine. Dehydration has caused kidney injury in people on these medicines.
• Swelling of the face, lips, tongue or throat, difficulty breathing, hives or a rapid heartbeat, which suggest a serious allergic reaction.
• Severe constipation with bloating, cramping and inability to pass stool or gas, which could indicate a bowel obstruction.
• Symptoms of very low blood sugar, particularly if you also take insulin or a sulfonylurea: shakiness, sweating, confusion, fainting.
• New or worsening thoughts of self-harm or sudden severe mood change.

Book a prompt appointment for:

• A lump or swelling in the neck, hoarseness, or trouble swallowing or breathing, which the labels ask you to report because of the thyroid warning.
• Sudden changes in vision, especially if you have diabetes.
• Nausea or other gastrointestinal effects that are not settling after the expected adjustment period, or that are affecting your nutrition.
• Rapid heartbeat at rest, new fatigue, or weight loss that feels faster than you or the prescriber intended.
• Any planned surgery, procedure requiring sedation, or intention to become pregnant, so the prescriber can advise on timing.
• A desire to switch from one medicine to the other, or to pause, reduce or stop. Never change the dose or stop on your own.

Follow-up visits are not a formality. They are where blood pressure, blood sugar, kidney function and side effects are checked and where the tirzepatide vs semaglutide decision gets revisited against your own results rather than a trial average. If you are unsure whether something is a red flag, calling the prescriber’s office or a nurse advice line is always the right move.

Frequently asked questions

Is tirzepatide better than semaglutide for weight loss?

On average, yes, based on the one large direct comparison. In SURMOUNT-5, adults without diabetes lost about 20% of body weight on tirzepatide versus about 14% on semaglutide over 72 weeks. That is a real difference, but semaglutide still produced substantial loss, individual responses varied widely in both groups, and semaglutide has stronger evidence for heart protection. Which is better for a given person depends on their health history, not on the average alone.

What is the difference between Wegovy vs Ozempic?

Both contain semaglutide, the same molecule. Ozempic is approved for type 2 diabetes and for reducing cardiovascular and kidney risk in people with diabetes. Wegovy is approved for chronic weight management, for reducing cardiovascular risk in people with heart disease and excess weight, and for MASH. The strengths studied and the approved purposes differ; the drug does not. Using the diabetes product for weight loss in someone without diabetes is off-label and a decision for the prescriber.

How long does it take to lose 20 lbs on tirzepatide?

It depends on starting weight and individual response. Trial participants averaging about 231 pounds had lost roughly 7% of body weight, around 16 pounds, by week 12 and about 15% by eight or nine months. A person matching that average might pass 20 pounds around the third or fourth month, but many lose more slowly or faster. The early months involve gradual dose increases directed by the prescriber, and rushing them does not speed results.

Why would a doctor prescribe semaglutide instead of tirzepatide?

Usually because of organ-protection evidence or formulation. Semaglutide has a randomized trial showing a 20% relative reduction in heart attacks, strokes and cardiovascular deaths in people with existing heart disease, plus specific evidence for kidney protection in diabetes and for MASH. It is also available as a daily tablet. A clinician may also choose it for a patient already stable on it, or based on tolerance, interactions or coverage. The decision weighs more than the weight-loss number.

Do you lose more muscle on semaglutide or tirzepatide?

The evidence cannot say. Body-composition substudies found about 40% of weight lost on semaglutide and about 25% on tirzepatide was lean mass, but those came from different trials with different participants and are not directly comparable. Both proportions fall within the range seen in diet-based weight loss. No head-to-head body-composition trial exists. Resistance training and adequate protein have far stronger evidence for preserving muscle than the choice between the two drugs.

What makes you less sick, semaglutide or tirzepatide?

They appear roughly equal. In the direct comparison, gastrointestinal side effects such as nausea, diarrhea and constipation occurred at similar rates and were mostly mild to moderate, clustering during dose increases. Slightly fewer people stopped tirzepatide because of side effects, about 6% versus about 8%, but the trial was not designed to prove a difference. Individual tolerance varies unpredictably, and symptoms usually ease with time and prescriber-guided adjustments.

Are Mounjaro vs Ozempic the same kind of drug?

They are closely related but not identical. Ozempic contains semaglutide, which activates the GLP-1 receptor. Mounjaro contains tirzepatide, which activates both the GLP-1 and GIP receptors. Both are approved for type 2 diabetes and taken weekly. In the SURPASS-2 trial, tirzepatide lowered HbA1c more and produced greater weight loss than the diabetes strength of semaglutide, while Ozempic carries approved heart and kidney protection indications that Mounjaro does not yet have.

Is Zepbound vs Mounjaro a real difference or just branding?

Both contain tirzepatide, so the medicine is the same. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity or overweight plus a related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity. The separate names reflect separate trials and approved uses, which matters for prescribing and coverage. Using either product outside its label is a decision that belongs to the treating clinician.

Can you switch from semaglutide to tirzepatide?

Switching is possible and is done in clinical practice, but only under a prescriber’s direction. The two drugs have different half-lives and strengths, so the transition has to be planned to avoid excessive side effects or gaps in treatment. Reasons for switching include inadequate response, side effects, a new diagnosis that favors one drug’s evidence, or changes in availability. Changing or stopping on your own is not advised for either medicine.

Are compounded tirzepatide or semaglutide products the same as the approved medicines?

No. Compounded versions are prepared by pharmacies rather than the original manufacturer and have not been reviewed by the FDA for safety, effectiveness or quality. Products marketed as research peptides are not approved for human use at all. Regulators have warned about dosing errors, contamination and counterfeit products in this category. They are not a substitute for a prescribed, approved medicine and are not intended for self-use; any treatment decision should go through a licensed clinician.

References

• MedlinePlus: Tirzepatide Injection
• MedlinePlus: Semaglutide Injection
• NIH NIDDK: Prescription Medications to Treat Overweight and Obesity
• PubMed: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.